
Opinion|Videos|April 18, 2025
Addressing Treatment Response and Switching Among Systemic Therapies in Atopic Dermatitis
Experts discuss how data from studies like JADE EXTEND, Heads Up Extension, and LEVEL UP, showing improved outcomes with JAK inhibitors in patients who failed biologic therapy, influence their clinical practice and decision-making when considering switching systemic therapies for patients with atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Several studies have shown that patients who have not responded to biologic therapy can achieve improved results when switching to a JAK inhibitor. How do these data impact your clinical practice and your threshold for switching systemic therapies for patients?
- JADE EXTEND
- Heads Up Extension; LEVEL UP
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5
























































